Thanks, I'm sure I'll learn at least a
few things from the thread. Of course the
Ariad toxic is old news, so I don't mind
bringing it up here (still long the stock,
but patience is nearly run out) and I see
there were already a smattering of posts
regarding it earlier.
My guess is that it is awfully late in the game
to get much more out of shorting Ariad--and I have
no love for the folks who do it, but if it adds to
the squeeze potential later, I guess that would
be okay <g>.
The much higher volumes of the last few days
and the lack of movement, up or down, in the
stock, suggest to me that this thing is under
pretty tight control now--and maybe some events
in the next few months will make things clearer.
It's unlikely that management would make such
a horrible mistake twice--and if anybody at the
company ever reads these boards, they already know
they've at least one pissed off shareholder. I
should think that Hoechst, which owns something
like ten percent of Ariad (forget the exact figure)
is more than a little disappointed in their investment.
To be sure I'm a bit of a hypocrite--I'd have been
delighted if a buck a share was the toxic induced low
for the stock--it's pretty obvious now that calling
the bottom in these things is next to impossible.
And everything from here depends on securing
partners, a lot of financing fears go away if
they ink a deal. That said, time for me to start
zipping through the thread.
One final thought however--another read of their
annual report reminds me that a lot of the details
are not revealed--various terms and conditions--some
of which may be kicking in now, some ten months after
the series C toxics were issued. That may be important,
and while I certainly would not suggest that anybody
go long or short this one, their scientific papers
of gene therapy regulation are a must read for anybody
interested in that stuff--regardless of where the stock
goes, it's remarkable stuff. |
